- Home
- SHEL vs ABBV Comparison
SHEL vs ABBV Comparison
Compare SHEL & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHEL | ABBV |
|---|---|---|
| Founded | 1907 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.5B | 358.5B |
| IPO Year | 2004 | 2012 |
Fundamental Metrics
Financial Performance| Metric | SHEL | ABBV |
|---|---|---|
| Price | $90.65 | $249.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 18 |
| Target Price | $93.79 | ★ $253.71 |
| AVG Volume (30 Days) | ★ 6.6M | 3.8M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | 3.25% | ★ 3.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.42 |
| Revenue | N/A | ★ $61,160,000,000.00 |
| Revenue This Year | $21.75 | $11.87 |
| Revenue Next Year | N/A | $8.12 |
| P/E Ratio | ★ $26.62 | $102.00 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $68.63 | $190.75 |
| 52 Week High | $94.90 | $267.47 |
Technical Indicators
Market Signals| Indicator | SHEL | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 51.05 |
| Support Level | $89.01 | $243.07 |
| Resistance Level | $91.98 | $263.35 |
| Average True Range (ATR) | 1.34 | 5.78 |
| MACD | -0.03 | -1.76 |
| Stochastic Oscillator | 69.44 | 30.72 |
Price Performance
Historical ComparisonAbout SHEL Shell PLC (each representing two (2))
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2025, it produced 1.5 million barrels of liquids and 7.3 billion cubic feet of natural gas per day. At year-end 2025, reserves stood at 8.1 billion barrels of oil equivalent, 44% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with a capacity of 1.4 mmb/d located in the Americas, Asia, and Europe, and sells about 9 million tons per year of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Northwestern Europe, China, and North America.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.